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Ramoplanin is an actinomycetes-derived antibiotic with broad-spectrum activity against Gram-positive bacteria that has been
evaluated in clinical trials for the treatment of gastrointestinal vancomycin-resistant enterococci (VRE) and Clostridium difficile
infections. Recent studies have proposed that ramoplanin binds to bacterial membranes as a C2 symmetrical dimer that can se-
quester Lipid II, which causes inhibition of cell wall peptidoglycan biosynthesis and cell death. In this study, ramoplanin was
shown to bind to anionic and zwitterionic membrane mimetics with a higher affinity for anionic membranes and to induce
membrane depolarization of methicillin-susceptible Staphylococcus aureus (MSSA) ATCC 25923 at concentrations at or above
the minimal bactericidal concentration (MBC). The ultrastructural effects of ramoplanin on S. aureus were also examined by
transmission electronmicroscopy (TEM), and this showed dramatic changes to bacterial cell morphology. The correlation ob-
served betweenmembrane depolarization and bacterial cell viability suggests that this mechanismmay contribute to the bacteri-
cidal activity of ramoplanin.
Ramoplanins A1, A2, and A3 (Fig. 1) are produced by Actino-planes sp. ATCC 33076 and slightly differ in their lipid sub-
stituents (1, 2). These lipoglycodepsipeptide antibiotics disrupt
cell wall biosynthesis (3–7) and possess potent activities against
Gram-positive bacteria, including methicillin-resistant Staphylo-
coccus aureus (MRSA), Staphylococcus epidermidis, streptococci,
vancomycin-resistant enterococci (VRE), Bacillus spp., Listeria
monocytogenes, and the anaerobe Clostridium difficile (8–11).
Ramoplanin is bactericidal at concentrations close to its MIC (12),
in contrast to vancomycin, which is bacteriostatic near its MIC. In
2006, Oscient Pharmaceuticals evaluated orally dosed ramopla-
nin, which is not systemically absorbed, in late-stage trials for the
treatment ofClostridiumdifficile-associated diarrhea (CDAD) and
VRE gastrointestinal colonization (13–16). Despite being admin-
istered intravenously to mice (17, 18), rats (17, 18), and rabbits
(19) in in vivo models, parenteral administration of ramoplanin in
humans is complicated due to hemolysis (13, 18, 20) and loss of
activity due to hydrolysis of the depsipeptide ester (14). Nano
Therapeutics, Inc., acquired the rights to develop ramoplanin in
2009 and recently announced that a phase IIb trial has been
scheduled for September 2014 to investigate the use ramopla-
nin (coded NTI-851) as a targeted prophylaxis for recently
treated patients with C. difficile infection (CDI) at high risk for
infection relapse (21).
An early mode-of-action study proposed that ramoplanin in-
hibited the intracellular glycosyltransferase (MurG)-catalyzed
conversion of Lipid I (undecaprenyl-pyrophospho-N-acetylmu-
ramyl-pentapeptide) to Lipid II (undecaprenyl-pyrophospho-N-
acetylmuramyl-N-acetylglucoseamine-pentapeptide) (3, 4), but
later studies by Walker and coworkers showed that ramoplanin
instead blocked the transglycosylation step of peptidoglycan bio-
synthesis by interfering with the transglycosylase-catalyzed extra-
cellular polymerization of Lipid II (5–7). A good correlation be-
tween the ability of ramoplanin to inhibit transglycosylation in
vitro (22) and its MICs against most Gram-positive strains sup-
ports this mechanism as its primary mode of action (14). Addi-
tional support for Lipid II as the primary target of ramoplanin is
its peripheral location on cell membranes, while Lipid I is found
exclusively on the cytoplasmic side of cell membranes (14). Also,
ramoplanin is unlikely to readily penetrate the bacterial mem-
brane due to its large size (molecular mass, 2,554 Da) and aqueous
solubility (100 mg/ml) (14, 23).
Ramoplanin contains an N-acyl chain linked to Asn-1 (Fig. 1)
(10, 14) which may insert into the bacterial membrane phospho-
lipid bilayers, as is the case for the lipoglycopeptide teicoplanin
(24, 25). Recent studies have proposed that ramoplanin forms an
intimate and highly amphipathic dimer in the membrane envi-
ronment and binds to bacterial membranes via its hydrophobic
interface (6, 26). In addition, the two positively charged ornithines
(Orn) at positions 4 and 10 (27) may also interact with anionic
phospholipids that predominate in Gram-positive bacteria (28,
29). Evidence for the membrane association of ramoplanin was
published by McCafferty and coworkers, who reported that ramo-
planin bound to phosphatidylethanolamine (PE) and phosphati-
dylglycerol (PG) phospholipid unilamellar vesicles in the absence
of Lipid II, but no experimental details were provided (26).
In this study, a dose-dependent membrane association of
ramoplanin was supported by results of surface plasmon reso-
nance (SPR) studies that also showed a propensity to bind prefer-
entially to anionic over zwitterionic membranes. Membrane ef-
fects of ramoplanin on methicillin-susceptible S. aureus (MSSA)
were assessed by using a combination of a membrane depolariza-
tion assay and transmission electron microscopy (TEM) exami-
nation of bacterial ultrastructures. Ramoplanin was shown to dis-
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sipate the membrane potential at concentrations close to or above
the minimal bactericidal concentration (MBC), which was consis-
tent with its rapid bactericidal activity against the MSSA strain
ATCC 25923.
MATERIALS AND METHODS
Antibiotics, bacterium, media, and phospholipids. Ramoplanin con-
taining 75% ramoplanin A2, vancomycin hydrochloride hydrate salt,
teicoplanin containing80% teicoplanin A2, and nisin from Lactococcus
lactis were purchased from Sigma-Aldrich (Sydney, Australia). Citropin
1.1 (GLFDVIKKVASVIGGL-NH2) was purchased from Chiron Mimo-
topes (Melbourne, Australia). MSSA ATCC 25923 was purchased from
the American Type Culture Collection (Manassas, VA). Mueller-Hinton
broth (MHB; Bacto Laboratories Pty. Ltd.) was used to grow MSSA for
determination of in vitro antibacterial activity in the presence and absence
of 50% human serum (Life Technologies Australia, Melbourne, Australia)
and time-kill assays. Luria-Bertani (LB) medium (Difco) and MHB
adjusted with Ca2 (25 mg/liter) and Mg2 (12.5 mg/liter) (CA-MHB)
were used for bacterial growth in the membrane depolarization assay
and TEM, respectively. The phospholipids used for SPR analysis,
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol(POPG),1-palmitoyl-2-ole-
oyl-sn-glycero-3-phosphocholine(POPC),and1-palmitoyl-2-oleoyl-sn-glycero-
3-phosphoethanolamine (POPE), were purchased from Auspep Pty. Ltd. (Mel-
bourne, Australia).
Antibacterial activity. MICs against MSSA ATCC 25923 were mea-
sured by broth microdilution according to the Clinical and Laboratory
Standards Institute (CLSI) M7-A7 methodology (30). Briefly, serial 2-fold
dilutions of each antibiotic were added into Costar nontreated polysty-
rene 96-well plates, and each well was inoculated with 50 l of MSSA in
MHB to a final concentration of approximately 5  105 CFU/ml. The
MIC was the lowest antibiotic concentration that showed no visible
growth after 24 h of incubation at 37°C. The dilution representing the
MIC and two of the more and less concentrated dilutions were plated out
onto Trypticase soy agar plates and enumerated to determine viable
CFU/ml (31). The MBC was the lowest concentration of antibiotic yield-
ing a 99.9% reduction in the initial colony count after 24 h of incubation.
Time-kill studies. Time-kill studies were carried out based on guide-
line M26-A of the CLSI (32), using Costar nontreated polystyrene 96-well
plates. The kill kinetics of ramoplanin against MSSA ATCC 25923
were tested by incubating an initial inoculum of approximately 5  105
CFU/ml with drug concentrations at the MIC, two dilutions above the
MIC (2 and 4MIC), and one dilution below the MIC (0.25MIC) in
MHB. Culture aliquots were mixed with the charcoal suspension (25 mg/
ml) to minimize antibiotic carryover. Viable cell counts were determined
after 0, 0.5, 1, 2, 4, 6, 8, and 24 h of incubation at 37°C by plating serially
diluted samples onto Trypticase soy agar plates. Bactericidal activity was
defined as a3-log10 CFU/ml decrease, in comparison with the baseline,
after 24 h of incubation (32). Vancomycin was used as a control, with drug
concentrations at 2, 1, and 0.5MIC. The time-kill assays were per-
formed twice independently, with similar results.
Liposome preparation. Lipid stock solutions were prepared in chlo-
roform and mixed at the described mass composition of POPC, POPC/
POPG (8:2, wt/wt) and POPC/POPE (8:2, wt/wt) (33), and the chloro-
form was evaporated as previously described (34). The lipids were
resuspended in 1 ml of filtered (0.22-m pore size) running buffer (phos-
phate-buffered saline [PBS]; pH 7.3) and then sonicated for 25 min in
5-min intervals. Small unilamellar vesicles (SUVs) were prepared by ex-
trusion through a polycarbonate filter with a 50-nm pore diameter (35).
SPR. SPR experiments were carried out with a Biacore T200 system
(GE Health, Australia) using a Biacore vesicle capture (L1) sensor chip,
which has lipophilic groups covalently attached to carboxymethylated
dextran that facilitates direct lipid bilayer deposition (34, 36). All mea-
surements were undertaken at a temperature of 25°C to maintain the lipid
bilayer fluidity (34). SUVs at a total lipid concentration of 0.5 mg/ml were
immediately passed across the chip surface for 60 min at a low flow rate of
2 l/min, following three 30-s injections of 20 mM 3-cholamidopropyl-
dimethylammonio-1-propane sulfonate (CHAPS) solution at a high flow
rate of 30 l/min to completely remove the captured vesicles from the
FIG 1 Structures of ramoplanin A1, A2, and A3, showing amino acid positional assignments and with the hydrophilic face (26) highlighted.
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sensor chip. To remove any multilamellar structures from the lipid sur-
face and to stabilize the baseline, 10 mM NaOH was injected for 1 min at
50 l/min. The coverage extent of the surface was later determined by a
5-min injection of 0.1 mg/ml bovine serum albumin (BSA) at a flow rate
of 10 l/min.
The antibiotics were serially diluted in running buffer and then in-
jected sequentially from the lowest (0.01 M) to the highest (10 M)
concentration at a flow rate of 20 l/min for 180 s, followed by a dissoci-
ation of 300 s and a 1-min regeneration with 10 mM HCl at a flow rate of
10 l/min. SPR experiments were performed in triplicate. The actual
amount of antibiotic bound to each lipid bilayer was corrected by subtrac-
tion of the bulk refractive index difference (buffer control) and then nor-
malized by dividing the antibiotic-bound resonance units (RUBound) ob-
tained in the SPR sensorgrams (see Fig. 3A, below) by the corresponding
antibiotic molecular weight and the resonance units of the individual lipid
vesicle captured on the chip surface (RULipid) (see Fig. S1 in the supple-
mental material) by using the following equation: normalized antibiotic
bound (103RUBound)/(molecular weightRULipid). Normalization
against molecular weight and RULipid was necessary, as SPR units are mass
dependent and RULipid values vary according to lipid type (37).
Membrane depolarization assay. Antibiotic-induced bacterial cyto-
plasmic membrane depolarization was determined by using the fluores-
cent dye 3,3-dipropylthiacarbocyanine [DiSC3(5); Sigma-Aldrich, Aus-
tralia] as previously described (38) with a high-throughput modification.
Briefly, mid-logarithmic-phase MSSA ATCC 25923 cells were collected by
centrifugation (5,000  rpm, 10 min), washed once and diluted to ap-
proximately 5 107 CFU/ml in buffer (5 mM HEPES, 5 mM glucose; pH
7.2). The cell suspension was incubated with 0.4 M DiSC3(5) until dye
uptake was maximal, as indicated by a stable reduction in fluorescence of
assay medium. KCl at 100 mM was added to equilibrate the cytoplasmic
and external K concentrations. A 90-l aliquot of cell suspension was
transferred into an Optiplate 96-well white microplate (PerkinElmer
Corp., Australia), and 10 l of antibiotic was added, to yield a series of
solutions ranging from 0.1 to 30 M. A blank with only cell suspension
and dye was used for background subtraction. The fluorescence intensity
was monitored in real time by using a BMG Labtech PolarStar Omega
multimode reader fitted with 620-10 and 665-10 excitation and emission
filters, respectively, at an excitation wavelength of 622 nm and an
emission wavelength of 670 nm. The membrane depolarization assays
were performed in triplicate, and the fluorescence leakage (FL) was
defined by the following equation: FL  (FF  FB)  (FI  FB). Here,
FF was the final fluorescence intensity in assay medium after 30 min of
treatment with antibiotic, FI was the initial fluorescence intensity of
the cell suspension, and FB was the fluorescence intensity of the blank.
Citropin 1.1 induces complete and stable fluorescence leakage at 10
M (0.5 MIC against MSSA ATCC 25923) (37) and was used to
normalize the membrane depolarization of other antibiotics using the
following formula: normalized membrane depolarization (as a per-
centage) FL(Antibiotic)/FL(Citropin 1.1 at 10 M) 100%.
TEM. Preparation and examination of ramoplanin- and vancomycin-
treated MSSA ATCC 25923 cells by TEM were performed as described
previously (39, 40). Exponential-phase bacteria in CA-MHB were ex-
posed to ramoplanin at 1 MIC or vancomycin at 16 MIC for 3 h at
37°C. After centrifugation (8,000  rpm, 3 min), the pellets were resus-
pended in 1 ml of 3% (vol/vol) glutaraldehyde in 0.1 M sodium cacody-
late. Glutaraldehyde–fixed samples were washed twice with 0.1 M sodium
cacodylate. To postfit cells, 1% (wt/vol) osmium tetraoxide was added.
After the wash step, samples were stained with 2% (wt/vol) uranyl
acetate in 50% ethanol. Samples were then dehydrated with graded
ethanol solutions and infiltrated with Epon resin (ProSciTech, Towns-
ville, Australia). All processes were performed on a Pelco 34700 Bio-
wave microwave oven (Ted Pella Inc., Redding, CA). Ultrathin sec-
tions were cut at 60 to 70 nm by using a UC6 ultramicrotome (Leica).
The sections were examined in a JEM 1011 TEM operated at 80 kV and
photographed using a digital camera.
RESULTS
Antibacterial activity. Ramoplanin displayed an MIC and an
MBC against MSSA ATCC 25923 of 2 and 4 g/ml, respectively,
consistent with the published MIC and MBC ranges (41–44). The
comparator antibiotics possessed the following MICs: vancomy-
cin (1 g/ml), teicoplanin (1 g/ml), nisin (32 g/ml), and citro-
pin 1.1 (32 g/ml). The MICs of ramoplanin and vancomycin in
the presence of 50% human serum were 0.5 and 2 g/ml, respec-
tively (see Table S1 in the supplemental material).
Ramoplanin is rapidly bactericidal at the MBC and above.
The MBC of ramoplanin was 2-fold higher than its MIC, which
was in agreement with a previous definition of bactericidal agents
(45). Time-kill curve analysis of MSSA ATCC 25923 showed rapid
bactericidal killing occurred when ramoplanin was present at its
MBC and above, as the viable cell counts decreased by approxi-
mately 5-fold within 1 h and by at least 1,000-fold (3 log10 CFU/
ml) in less than 4 h when tested at the MBC and above (Fig. 2A).
This was consistent with its reported bactericidal activity against
antibiotic-resistant enterococci (12) and MRSA (46). There
was a reduction of 3 log10 CFU/ml observed when MSSA
ATCC 25923 was exposed to vancomycin at the MBC and
above for 8 h (Fig. 2B), which was in agreement with results in
previous studies (47, 48).
Ramoplanin binds tomembranes in a dose-dependentman-
ner with higher affinity for anionic over zwitterionic mem-
branes. SPR studies using a Biacore L1 biosensor chip (36, 37, 49)
were used to gain insight into interactions of ramoplanin with
phospholipid bilayers representing mammalian and bacterial
membranes. In this study, the zwitterionic phospholipids POPC
FIG 2 Time-kill curves of MSSA ATCC 25923 exposed to ramoplanin (A) and
vancomycin (B) at different concentrations in relation to their respective MICs
over a period of 24 h. The growth control contained no antibiotics. The limit of
detection was 100 CFU/ml. Mean values of duplicate CFU/ml measurements
are plotted.
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and POPE were used to mimic more neutral mammalian cell
membranes, while the anionic phospholipid POPG was used in
combination with POPC to mimic more anionic bacterial cell
membranes (37, 50). The immobilization of phospholipid bilayer
on the chip was measured as the changes in resonance units (RU)
against time, and the amount of lipid loaded (RUlipid) varied de-
pended upon the lipid types: 3,000 RU for POPC:POPG (8:2),
7,000 RU for POPC and 8,000 RU for POPC:POPE (8:2) (see Fig.
S1 in the supplemental material). Using the established correla-
tion between RU and absorbed mass (1 RU 1 pg/mm2) (51, 52),
the POPC:POPG, POPC, and POPC:POPE membranes had sur-
face densities equivalent to approximate 3, 7, and 8 ng/mm2, re-
spectively. These findings lead to the theoretical surface density
for a perfect, unilamellar planar phospholipid bilayer of 4.4 ng/
mm2 (52).
Ramoplanin was then injected across the stable phospholipid
bilayers in a series of concentrations ranging from 0.01 to 10 M,
giving rise to the resulting sensorgrams that showed the changes in
RU as a function of time upon binding of ramoplanin to the mi-
metic membranes (RUBound) (Fig. 3A). Low concentrations (0.01
to 1 M) of ramoplanin showed a negligible association, while
high concentrations (3 and 10 M) showed a significant associa-
tion with binding responses, up to approximate 6,000 RU for both
anionic and zwitterionic membranes. Ramoplanin at concentra-
tions ranging from 0.01 to 1 M showed complete dissociation
after completion of the injection, whereas ramoplanin at concen-
trations of 3 and 10 M had a gradual dissociation, with approx-
imately 40% to 60% of material remaining on membranes at 480 s.
These data showed that ramoplanin bound to both anionic and
zwitterionic membranes in a dose-dependent manner.
Comparison of the binding affinities of ramoplanin toward
each of the three different lipid bilayers required normalization
of the RUBound value against the molecular weight and the value
RULipid for the respective phospholipid bilayer (37), and the
values were ranked as follows: POPC:POPG (8:2)  POPC 
POPC:POPE (8:2) (Fig. 3B). There was a significant preference
for POPC:POPG (8:2) anionic membrane over either zwitteri-
onic membranes (P 	 0.001). The difference between the two
zwitterionic membranes may have resulted from different mem-
brane packing, as the smaller headgroup of POPE compared to
POPC can lead to tighter membrane packing (53).
Citropin 1.1, which has been reported to selectively bind to
anionic membranes (37), displayed similar membrane specificity
to ramoplanin but had significantly reduced binding affinity (Fig.
3B). Nisin showed no binding to either anionic or zwitterionic
phospholipid bilayers, which was in agreement with findings of a
previous model membrane study (54). Vancomycin displayed
negligible binding to each of the three different membranes,
consistent with previous SPR study results (36, 37). Teicoplanin
bound preferentially to the anionic membrane over zwitterionic
membranes, which may potentially be attributed to its fatty acyl
chain and amine moieties.
Ramoplanin causes dose-dependent bacterialmembranede-
polarization. Ramoplanin-induced cytoplasmic membrane po-
tential change was determined by measuring the effect of ramo-
planin on MSSA ATCC 25923 membrane potential gradient
FIG 3 (A) Typical SPR sensorgrams, showing the changes in resonance units (RU) against time upon binding of ramoplanin (0.01 to 10 M) to lipid bilayers
comprised of different lipid mixtures reconstituted on an L1 lipid capture sensor chip. Ramoplanin was injected over the lipid surface for 180 s, and the
ramoplanin-lipid complex was then allowed to dissociate for 300 s. The baseline was set to zero for ease of visualization and represents the value RULipid. (B)
Comparison of the binding affinities of antibiotics toward three different lipid bilayers at 10 M, after normalization of the amount of antibiotic bound
(RUBound) in SPR sensorgrams against the corresponding antibiotic molecular weight and the amount of lipid loaded on each channel of the sensor chip
(RULipid), as described in Materials and Methods. Statistical comparisons of normalized antibiotic bound to the anionic (POPC:POPG, 8:2) and zwitterionic
(POPC and POPC:POPE, 8:2) membranes was performed by using the two-tailed Student t test. **, P 	 0.01; ***, P 	 0.001. Data are means 
 standard
deviations (n 3).
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depolarization, using the membrane potential-sensitive dye
DiSC3(5) (37, 38). In this assay, DiSC3(5) localizes in the bacterial
membrane according to the intact membrane potential gradient,
where the fluorescence is self-quenched (55, 56). Compounds that
depolarize the membrane potential gradient release the mem-
brane-bound DiSC3(5) into the assay medium, where fluores-
cence can be measured (56). Citropin 1.1, which rapidly depolar-
izes cytoplasmic membrane due to pore formation (37), was used
as a positive control, whereas vancomycin was used as a negative
control, as it does not directly compromise membrane integrity
(57). Citropin 1.1 triggered a rapid and complete fluorescence
leakage at 0.5MIC (10M) and higher concentrations within
30 min (see Fig. S2 in the supplemental material), while no leakage
was observed after the addition of vancomycin at 12MIC for a
period of 30 min (Fig. 4), which was consistent with a previous
study (37). Nisin was shown to depolarize bacterial membranes at
a concentration as low as 0.25MIC and caused dramatic mem-
brane depolarization at the MIC and above (Fig. 4), which was in
agreement with previous study (58, 59). Ramoplanin was shown
to cause dose-dependent membrane depolarization but less effi-
ciently than nisin: for ramoplanin, 3 MIC was required to de-
polarize the cells to a similar extent as 0.25 MIC nisin (Fig. 4).
Depolarization induced by ramoplanin was significantly stronger
than that of teicoplanin, which triggered measurable but minor
fluorescence leakage at concentrations significantly higher than
the MIC (Fig. 4).
Ramoplanin causes morphological changes to the bacterial
cell wall and cellmembranes.Untreated MSSA ATCC 25923 cells
exhibited a normal coccoid shape (circular and smooth), sur-
rounded by a clear and intact cell membrane and cell wall with a
uniform thickness of 25 to 30 nm (Fig. 5A) and with a prominent
septal midline within the nascent septum (Fig. 5B), consistent
with previous microscopy studies (40, 60, 61). The vast majority of
MSSA cells exposed to ramoplanin displayed deformed septa that
were slightly thickened, misshapen, and lacked distinct septal
midlines (Fig. 5C), while exposure to vancomycin did not cause
septal deformation or loss of midline (see Fig. S3A in the supple-
mental material). Ramoplanin-treated MSSA cells also showed
irregular thickening and an increase in the occurrence of “fuzzy”
cell walls (Fig. 5D), as was the case for vancomycin (see Fig. S3B).
In addition to morphological changes to septa and cell walls,
ramoplanin elicited cell membrane alterations, demonstrated by
the appearance of mesosome structures in cell membranes (Fig.
5E), which were absent in vancomycin-treated MSSA cell mem-
branes. Cytoplasmic contents were further released from the dis-
rupted cells to form ghost cells (Fig. 5F).
DISCUSSION
Gram-positive bacterial membranes are negatively charged due to
the presence of PG and to a lesser extent cardiolipins (28, 29),
while mammalian membranes contain a high proportion of zwit-
terionic phospholipids PE and PC (62). As the PE content of some
mammalian cells is around 20%, a POPC:POPE (8:2, wt/wt) mix-
ture was used as a mammalian membrane mimic for SPR studies.
Similarly, a POPC:POPG (8:2, wt/wt) mixture was used to mimic
a simplified bacterial membrane (29, 63).
Ramoplanin has been proposed to form an amphipathic C2
symmetrical dimer that has a membrane binding hydropho-
bic surface and a hydrophilic surface, in which Lipid II is cap-
tured between the two hydrophobic surfaces of the dimer (15).
McCafferty and coworkers have reported without experimental
details that ramoplanin binds to PE and PG unilamellar vesicles in
the absence of Lipid II (26, 27) In this study, SPR was used to show
that ramoplanin binds to both anionic and zwitterionic mem-
branes at concentrations of 3 M and above in a dose-dependent
manner, with enhanced selectively for anionic over zwitterionic
membranes. Nisin did not bind to any of the membranes in these
SPR studies, which was consistent with previous studies that
showed nisin specifically bound to the Lipid II pyrophosphate
moiety (Kd of 10
8 M) rather than phospholipid bilayers (Kd of
104 M) (54, 64, 65).
The increased binding affinity of ramoplanin for anionic mem-
branes over zwitterionic membranes was similar to that reported
for citropin 1.1 (37). The selectivity of citropin 1.1 for anionic
membranes has been suggested to be due to the electrostatic in-
teraction of the positively charged (2) citropin 1.1 with the neg-
atively charged PG headgroups (37, 66). Previous studies have
shown that the Orn-10 residue occupies the hydrophobic/hydro-
philic interface of the ramoplanin dimer, while the Orn-4 residue
lies on the hydrophilic interface (6, 26). Therefore, Orn-10 is in a
suitable position to make long-range electrostatic and ion-dipole
contacts with the PG headgroups that may be responsible for the
membrane selectivity of ramoplanin. The importance of the Orn
residues in ramoplanin was demonstrated during an alanine scan
study in which the replacement of the Orn-10 residue resulted in a
540-fold loss of activity, while replacement of Orn-4 led to a 44-
fold loss in activity (67). Hence, Orn-10 may play a dual role in the
mode of action by binding to the Lipid II pyrophosphate moiety
(26) and binding preferentially to bacterial membranes.
FIG 4 Antibiotic-induced membrane depolarization, demonstrated by the
fluorescence leakage from MSSA ATCC 25923 following 30 min of antibiotic
treatment, as a function of the fold change for the respective MIC (A) and as a
function of the concentration (inM) (B) against MSSA ATCC 25923, relative
to the complete leakage observed for the known pore-forming antibacterial
peptide citropin 1.1 at 0.5 its MIC (10M). Means
 standard deviations
are shown (n 3).
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The hydrophobic acyl chain allows ramoplanin to anchor and
insert into the phospholipid bilayer in a transmembrane manner,
as is the case for teicoplanin (68, 69), while nisin requires Lipid II
to be incorporated into the membrane to trigger membrane
insertion. Once bound to the membrane, nisin undergoes Lipid
II-induced aggregation that causes membrane disruption and
leakage (54). Ramoplanin has been shown to undergo Lipid
II-induced aggregation in vitro (5, 27, 70), which could also be
occurring on the bacterial membrane surface. Both ramopla-
nin and teicoplanin caused dose-dependent membrane depo-
larization in a weak detergent-like manner without immediate
loss of the entire membrane integrity (Fig. 4), whereas citropin
1.1 triggered a sudden and detergent-like membrane disrup-
tion regardless of concentration (see Fig. S2 in the supplemen-
tal material), which appeared to adopt the membrane-disrup-
tive (“carpet-like”) mechanism (71).
TEM images of untreated and vancomycin-treated MSSA
showed the presence of dividing cells with highly contrasted septal
FIG 5 TEM images of MSSA ATCC 25923 at mid-log phase (A and B). Untreated bacteria are spheroidal with a distinct septal midline (arrows in panel B). After
incubation with ramoplanin at a concentration of 1MIC for 3 h, bacteria presented with deformed septa (arrow in panel C), irregular thickening cell wall (D),
mesosomes (arrows in panel E), and lysis of the membrane (F), resulting in leakage of cytosolic contents. Bars, 200 nm.
Cheng et al.
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midlines, which result from autolysins that hydrolyze polymers of
the nascent cross walls, exposing an electron-dense staining area
within the septum (40). Exposure to ramoplanin caused septal
deformations, and loss of the septal midline could be due to ramo-
planin-induced cell wall biosynthesis inhibition (5, 6) or/and
membrane depolarization that could affect autolysin activity,
which is important in the regulation of autolysis (40, 72). Addi-
tionally, ramoplanin elicited obvious cell membrane changes as
indicated by the formation of mesosome structures, which are
intracytoplasmic membrane inclusions and have been regarded as
the indication of cytoplasmic membrane alteration (38). Since the
cytoplasmic membrane is essential for cell wall synthesis and turn-
over, the cytoplasmic membrane alteration may also affect cell
wall integrity (73), as indicated by the irregular thickening and
more “fuzzy” cell walls of ramoplanin-treated MSSA.
Ramoplanin inhibits the transglycosylation step of peptidogly-
can biosynthesis, with a 50% inhibitory concentration (IC50) of
0.25MIC (Fig. 6) (22), suggesting that transglycosylation inhi-
bition is the primary mode of action of ramoplanin. In this study,
ramoplanin was shown to trigger rapid dose-dependent mem-
brane depolarization at concentrations of 3 MIC and above,
which was close to its MBC of 2MIC against MSSA ATCC 25923
(Fig. 6). Time-kill studies indicated that ramoplanin exhibited
rapid bactericidal activity at concentrations equal to or above the
MBC, producing a 5-fold decrease in viability within 1 h and bac-
tericidal activity (9%) in less than 4 h.
The importance of the membrane depolarization and bacteri-
cidal killing in vivo is difficult to quantify due to the limited pub-
lished pharmacokinetic (PK) studies (18, 19), as well as its non-
systemic oral administration in human clinical trials. In addition,
MIC determinations can be highly dependent on plate type, se-
rum, and BSA (18, 41). The first reported PK properties of ramo-
planin were published in 1986, when a daily 10-mg/kg of body
weight intravenous (i.v.) dosing in rabbits of ramoplanin alone
and ramoplanin with penicillin resulted in maximal ramoplanin
plasma levels (Cmax) of 28 g/ml (11 M; 14MIC) and a 12-h
concentration (C12) of 6.4 g/ml (2.5 M; 3 MIC) (19) when
using the agar dilution method. The ramoplanin MIC in this study
against two VRE strains was 0.5 g/ml and the addition of 10%
serum increased the MIC to 2 g/ml (19). In a recent publication
a 20-mg/kg i.v. dosing of ramoplanin in rats gave a Cmax of 79
g/ml (31M; 39MIC) and a C12 of 2g/ml (0.8M; 1MIC)
using the agar dilution method (18). This study also reported that
the MIC of ramoplanin was not affected by the addition 50%
human serum for MSSA and MRSA strains (18). In our study, the
ramoplanin MIC against MSSA ATCC 25923 in the presence of
50% human serum lowered the MIC from 2 to 0.5 g/ml (see
Table S1 in the supplemental material). The initial concentrations
of ramoplanin in in vivo studies (18, 19) were above levels in which
the in vitro ramoplanin-induced membrane depolarization and
bactericidal killing can occur, while the presence of serum did not
adversely the MICs for staphylococci. These data suggest that
there is potential clinical relevance for ramoplanin-induced mem-
brane depolarization and that this depolarization could contrib-
ute to the characteristic rapid bactericidal activity of ramoplanin.
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